Cosciens Biopharma
(OTC) CSCIF
Cosciens Biopharma Financials at a Glance
Market Cap
$6.46M
Revenue (TTM)
$8.18M
Net Income (TTM)
$10.38M
EPS (TTM)
$-3.27
P/E Ratio
-0.62
Dividend
$0.00
Beta (Volatility)
0.72 (Low)
Dividend
$0.00
Beta (Volatility)
0.72 (Low)
Price
$2.03
Volume
4,820
Open
$2.03
Price
$2.03
Volume
4,820
Open
$2.03
Previous Close
$2.03
Daily Range
$2.03 - $2.06
52-Week Range
$0.79 - $4.40
Dividend
$0.00
Beta (Volatility)
0.72 (Low)
Price
$2.03
Volume
4,820
Open
$2.03
Previous Close
$2.03
Daily Range
$2.03 - $2.06
52-Week Range
$0.79 - $4.40
CSCIF News
Aeterna Zentaris Names New CEO
This Week in Biotech
This Week in Biotech
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Cosciens Biopharma
Industry
Biotechnology
Sector
Health CareEmployees
28
CEO
Peter Harry Puccetti, CFA
Website
www.cosciensbio.comHeadquarters
Toronto, ON M5K 1E7, CA
CSCIF Financials
Key Financial Metrics (TTM)
Gross Margin
32%
Operating Margin
-1%
Net Income Margin
-1%
Return on Equity
-122%
Return on Capital
-60%
Return on Assets
-49%
Earnings Yield
-1.61%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$6.46M
Shares Outstanding
3.18M
Volume
4.82K
Short Interest
0.00%
Avg. Volume
3.34K
Financials (TTM)
Gross Profit
$2.69M
Operating Income
$10.62M
EBITDA
$9.41M
Operating Cash Flow
$8.61M
Capital Expenditure
$717.77K
Free Cash Flow
$9.33M
Cash & ST Invst.
$7.29M
Total Debt
$2.14M
Cosciens Biopharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$1.79M
-46.1%
Gross Profit
$617.86K
-69.8%
Gross Margin
34.48%
N/A
Market Cap
$6.46M
N/A
Market Cap/Employee
$161.59K
N/A
Employees
40
N/A
Net Income
$2.21M
+67.1%
EBITDA
$2.13M
+59.3%
Quarterly Fundamentals
Net Cash
$5.14M
-63.5%
Accounts Receivable
$1.26M
-49.1%
Inventory
$1.30M
-51.6%
Long Term Debt
$1.93M
-5.4%
Short Term Debt
$214.43K
-60.4%
Return on Assets
-48.56%
N/A
Return on Invested Capital
-60.24%
N/A
Free Cash Flow
$1.54M
+53.6%
Operating Cash Flow
$1.49M
+50.3%